Context
DBV Technologies has been dual-listed on Nasdaq since October 2014.
PEPITES phase III results were released in October 2017 and showed a 35.5% responder rate vs. 13.6% for the placebo at a 250ug dose (p=0.00001) with a strong safety profile.
Viaskin Peanut BLA was filed in August 2019 and accepted for review by the FDA in October 2019.
Viaskin Milk phase 2 results released in February 2018 validated further the EPIT platform.
DBV Technologies will use the proceeds to prepare commercialization of Viaskin Peanut if approved, advance development of other product candidates, and for general corporate purposes.
About DBV
DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food-allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical trial of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co accompanies DBV on its USD 143 million NASDAQ Follow-on
Gross proceeds of USD 143 million (including 15% greenshoe option) on the back of substantial demand.
Price of €12.04 per ordinary share at a discount of 14.9% to the VWAP of the trading day prior to pricing.
14% of the issue in the form of ordinary shares and 86% in the form of ADSs.
Transaction anchored by Baker Bros Advisors and existing shareholders for USD 60 million.
This offering is the 4th NASDAQ transaction Bryan, Garnier & Co has helped lead for DBV Technologies.
Share